Fundz

Rhapsogen Appoints Renato Skerlj, Ph.D., as Chief Executive Officer

PRIVATEJan 06, 2026

Position

Chief Executive Officer

Company

Rhapsogen

Renato Skerlj
CambridgeBiotechnologyHealth CareTherapeutics

Description

Rhapsogen has announced the immediate appointment of Renato Skerlj, Ph.D., as its new Chief Executive Officer. Dr. Skerlj brings over 30 years of drug development experience to the biotech startup as it aims to develop next-gen autoimmune treatments.

Quick answer

Rhapsogen Appoints Renato Skerlj, Ph.D., as Chief Executive Officer (January 6, 2026). Rhapsogen is based in Cambridge, Massachusetts, United States.

Who is the new Chief Executive Officer at Rhapsogen?
Rhapsogen named Renato Skerlj Chief Executive Officer, announced January 6, 2026.
What did Rhapsogen announce on January 6, 2026?
Rhapsogen has announced the immediate appointment of Renato Skerlj, Ph.D., as its new Chief Executive Officer. Dr. Skerlj brings over 30 years of drug development experience to the biotech startup as it aims to develop next-gen autoimmune treatments.
What does Rhapsogen do?
Rhapsogen is a Cambridge, MA-based immunology company focused on redefining the autoimmune treatment paradigm by developing next generation therapies that rapidly neutralize pathogenic autoantibodies and prevent...
Where is Rhapsogen based?
Rhapsogen is based in Cambridge, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
Mezzion Pharma (January 6, 2026), NuCana (January 6, 2026), Damora Therapeutics, Inc. (January 6, 2026) and Archeus Technologies (January 7, 2026) also announced leadership changes within 45 days of Rhapsogen.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Rhapsogen, and when

A new leader at Rhapsogen brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Rhapsogen raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Rhapsogen, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Rhapsogen. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Rhapsogen

Location

Cambridge, Massachusetts, United States

About

Rhapsogen is a Cambridge, MA-based immunology company focused on redefining the autoimmune treatment paradigm by developing next generation therapies that rapidly neutralize pathogenic autoantibodies and prevent autoimmune inflammation and tissue damage while preserving the immune system’s ability to fight infection. The company was founded in 2025 by Dr. Jeffrey Ravetch (Rockefeller University) and Dr. Eric Sundberg (Emory University).

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Rhapsogen changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Rhapsogen's next move

Learn about Strategic plan

Rhapsogen changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.